Subdued Growth No Barrier To Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Price

With a price-to-sales (or "P/S") ratio of 23.1x Kymera Therapeutics, Inc. (NASDAQ:KYMR) may be sending very bearish signals at the moment, given that almost half of all the Biotechs companies in the U

Simply Wall StJun 27 18:07

Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033

PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer

GlobeNewswireJun 20 20:45

Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics

Ratings for Kymera Therapeutics (NASDAQ:KYMR) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.Summarizing their recent assessments, the table

BenzingaJun 17 20:00

H.C. Wainwright Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $46

H.C. Wainwright analyst Andrew Fein maintains $Kymera Therapeutics(KYMR.US)$ with a buy rating, and maintains the target price at $46.According to TipRanks data, the analyst has a success rate of 49.4

Futu NewsJun 17 19:31 · Ratings

Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $56

Piper Sandler analyst Edward Tenthoff maintains $Kymera Therapeutics(KYMR.US)$ with a buy rating, and maintains the target price at $56.According to TipRanks data, the analyst has a success rate of 33

Futu NewsJun 17 18:33 · Ratings

Kymera Therapeutics(KYMR.US) Director Sells US$950.17K in Common Stock

$Kymera Therapeutics(KYMR.US)$ Director Booth Bruce sold 26,940 shares of common stock on Jun 12, 13, 2024 at an average price of $35.27 for a total value of $950.17K.Source: Announcement What is stat

Futu NewsJun 15 06:43